Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Intravitreal injection of anti vascular endothelial growth factor agent, Lucentis (ranibizumab), for the treatment of retinopathy of prematurity

Next Previous
Trial Profile

Intravitreal injection of anti vascular endothelial growth factor agent, Lucentis (ranibizumab), for the treatment of retinopathy of prematurity

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 05 Dec 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Retinopathy of prematurity
  • Focus Therapeutic Use

Most Recent Events

  • 03 Dec 2017 Planned End Date changed from 1 Jun 2019 to 30 Jun 2019.
  • 03 Dec 2017 Status changed from not yet recruiting to discontinued.
  • 10 Jul 2014 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top